

Cellzome Factsheet

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of specific drug candidates for the treatment of inflammatory diseases. Our pipeline of small-molecule therapeutics is driven by *Kinobeads*[™], a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*[™] to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

The Company is domiciled in the US and employs about 90 people at its two operating companies in Heidelberg, Germany and Cambridge, UK.

Management team has strong scientific and commercial credentials. The Company is also backed by some of the biotech industry's most experienced investors.

Strategy is to commercialize the technology and assets by building a small molecule pipeline in inflammation and by collaborating with pharma partners.

Technology - *Kinobeads*[™] can define the target profile of kinase inhibitor drugs and is used as a versatile assay in screening and lead optimization using native kinases directly from cells and tissues.

A new technology, *Episphere*[™], is being used to identify novel drug candidates for epigenetic targets in their protein complexes.

Pipeline - Small molecule therapeutics for inflammatory diseases with a focus on kinase targets.

- The most advanced program, targeting PI3Ky, is anticipated to enter the clinic in 2010.
- Several other programs are in early preclinical testing.

Collaborations

- ***Episphere*[™] collaboration** in inflammatory diseases with GSK. A worldwide strategic drug discovery alliance in the field of epigenetics.
- ***Kinobeads*[™] collaboration** in inflammatory diseases with GSK. A worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.
- **Collaborations** with both Johnson & Johnson and Novartis were successfully completed.

Cellzome Inc.

Founded: May 2000

Number of Employees: about 90

Board of Directors

Charles Cohen, PhD

Chairman,
Advent International

Timothy P. W. Edwards

Chief Executive Officer

Johnston L. Evans

Invesco Private Capital

Jason S. Fisherman, MD

Advent International

Jean-François Formela, MD, MBA

Atlas Venture

Stelios Papadopoulos, PhD

Francesco De Rubertis, PhD

Index Ventures

Senior Management Team

Timothy P. W. Edwards

Chief Executive Officer

David Simmons, PhD, MBA

Chief Scientific Officer

Jane Dancer, PhD, MBA

Vice President Business Development

Gerard Drewes, PhD

Vice President Discovery Research

Richard Hale, PhD

Vice President Development Projects
& UK Site Head

Gitte Neubauer, PhD

Vice President Research Operations

Nigel Ramsden, PhD

Vice President Drug Discovery

Oliver Rausch, PhD

Vice President Biology

Markus Reinhard

Vice President Finance &
Administration

Locations

Cellzome AG

Meyerhofstrasse 1
69117 Heidelberg
Germany
Tel: +49 (0) 6221 137 57 0
Fax: +49 (0) 6221 137 57 201

Cellzome Limited

Chesterford Research Park
Little Chesterford
Cambridge, CB10 1XL
United Kingdom
Tel: +44 (0) 1799 532 800
Fax: +44 (0) 1799 532 801

Investors

Advent International

Atlas Venture

Astellas Venture Capital

Biofrontier Partners

Heidelberg Innovation

Index Ventures

Invesco Private Capital

SV Life Sciences

SG Asset Management

Sofinnova Partners

Recent News

March 2010: Cellzome announces second major strategic Drug Discovery Alliance with GlaxoSmithKline in inflammatory disease

November 2009: Cellzome advances understanding of Hepatitis C

September 2009: Cellzome announces achievement of fourth milestone in inflammation alliance with GlaxoSmithKline